Abstract | BACKGROUND: PATIENTS AND METHODS: 144 patients with lung adenocarcinoma undergoing surgical resection were studied. Quantitative real-time reverse transcriptase polymerase chain reaction and Immunohistochemistry were used to analyze EMX2 mRNA and protein expression, respectively. Association of EMX2 mRNA expression levels with clinical outcomes was evaluated using the Kaplan-Meier method and a multivariate Cox proportional hazards regression model. RESULTS: EMX2 mRNA expression was significantly downregulated in lung adenocarcinoma compared with matched adjacent normal tissue (P < .001). EMX2 protein expression was similarly found to be downregulated in lung adenocarcinoma. The EMX2-high mRNA expressing group had statistically significant better overall survival (OS) than the EMX2-low mRNA expressing group (P = .005). Subgroup analysis also demonstrated improved survival in stage I patients (P = .01) and patients with BAC (P = .03). Lastly, the EMX2-high mRNA expressing group had statistically significant better recurrence-free survival (RFS) than the EMX2-low mRNA expression group in patients with adenocarcinoma (P < .001). CONCLUSION: EMX2 expression is downregulated in lung adenocarcinoma. Low EMX2 mRNA expression is significantly associated with decreased OS and RFS in patients with lung adenocarcinoma, particularly with stage I disease and BAC.
|
Authors | Junichi Okamoto, Johannes R Kratz, Tomomi Hirata, Iwao Mikami, Dan Raz, Mark Segal, Zhao Chen, Hai-Meng Zhou, Patrick Pham, Hui Li, Adam Yagui-Beltran, Adam Beltran, M Roshni Ray, Kiyoshi Koizumi, Kazuo Shimizu, David Jablons, Biao He |
Journal | Clinical lung cancer
(Clin Lung Cancer)
Vol. 12
Issue 4
Pg. 237-44
(Jul 2011)
ISSN: 1938-0690 [Electronic] United States |
PMID | 21726823
(Publication Type: Comparative Study, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2011 Elsevier Inc. All rights reserved. |
Chemical References |
- Antineoplastic Agents
- Homeodomain Proteins
- RNA, Messenger
- Transcription Factors
- empty spiracles homeobox proteins
|
Topics |
- Adenocarcinoma
(genetics, secondary, therapy)
- Adenocarcinoma, Bronchiolo-Alveolar
(genetics, secondary, therapy)
- Adult
- Aged
- Antineoplastic Agents
(therapeutic use)
- Carcinoma, Non-Small-Cell Lung
(genetics, secondary, therapy)
- Down-Regulation
- Female
- Follow-Up Studies
- Homeodomain Proteins
(genetics)
- Humans
- Lung
(metabolism, pathology)
- Lung Neoplasms
(genetics, pathology, therapy)
- Male
- Middle Aged
- Neoplasm Staging
- Prospective Studies
- RNA, Messenger
(genetics)
- Reverse Transcriptase Polymerase Chain Reaction
- Survival Rate
- Transcription Factors
(genetics)
- Treatment Outcome
|